Small molecule · developed by Neumora Therapeutics
Navacaprant (NMRA-335140) is an orally administered agent studied at 80 mg once daily over a 52-week treatment period in major depressive disorder and in major depressive episodes associated with bipolar II disorder.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06029439 | Phase 3 | Major Depressive Disorder | Terminated | NMRA |
| NCT06429722 | Phase 2 | Major Depressive Episode Associated With Bipolar II Disorder | Completed | NMRA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Major Depressive DisorderMajor Depressive Episode Associated With Bipolar II Disorder
Updated Oct 25, 2026. Something wrong or missing? Report it on the NMRA page.
See NMRA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NMRA catalysts and pipeline →